Genome-wide CRISPR-Cas 9 screens identify BCL family members as modulators of response to regorafenib in experimental glioma

Registered systemic treatment options for glioblastoma patients are limited. The phase II REGOMA trial suggested an improvement of median overall survival in progressive glioblastoma by the multi-tyrosine kinase inhibitor regorafenib. This has not been confirmed by GBM AGILE. So far, regorafenib has...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Neuro-oncology (Charlottesville, Va.) Va.), 2025-01
Hauptverfasser:	Haeusser, Lara Annina, Becker, Hannes, Kuhlburger, Laurence, Zago, Marcello, Walter, Bianca, Tsiami, Foteini, Erdmann, Sarah, Trampert, Jil, Surender, Surender, Stahl, Aaron, Templin, Markus, Wegner, Eileen, Schmidt, Tobias, Schmees, Christian, Casadei, Nicolas, Sevenich, Lisa, Claassen, Manfred, Nahnsen, Sven, Beck, Susanne, Merk, Daniel Josef, Tabatabai, Ghazaleh
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!